Table 4.

Multivariate analysis--impact of SPM on OS

Covariate	N	Hazard ratio	95% Hazard ratio confidence limits		P-value
Time-dependent: SPM
No	-	1	Reference		<.0001
Yes	-	3.85	2.95	5.02	<.0001
Baseline covariates
Gender
Female	1791	1.00	Reference		.2683
Male	2155	1.09	0.94	1.27	.2683
Race
Black	1356	1.00	Reference		.0129
White	2300	1.27	1.07	1.51	.0068
Other	204	0.82	0.53	1.25	.3492
Missing	86	0.98	0.54	1.75	.9351
Karnofsky score
≥90	2076	1.00	Reference		.009
<90	1796	1.27	1.09	1.49	.0021
Missing	74	1.16	0.63	2.12	.6297
HCT-CI
0	1030	1.00	Reference		.1121
1-2	1237	1.03	0.84	1.27	.7629
3+	1659	1.21	1.00	1.47	.0547
Missing	20	0.38	0.05	2.69	.329
ISS stage at diagnosis
Stage I	1231	1.00	Reference		<.0001
Stage II	1104	1.31	1.05	1.62	.0152
Stage III	712	1.91	1.54	2.38	<.0001
Missing	899	1.39	1.11	1.74	.0046
Cytogenetics
Standard/Normal Risk	2496	1.00	Reference		<.0001
High risk	1114	2.11	1.79	2.48	<.0001
Missing	336	1.48	1.13	1.95	.0048
Lines of chemotherapy
1	2856	1.00	Reference		.0005
2+	929	1.40	1.18	1.65	<.0001
Missing	161	1.04	0.66	1.64	.8805
Disease status before transplant
sCR/CR	611	1.00	Reference		.0081
VGPR	1538	1.14	0.89	1.46	.3154
PR	1520	1.22	0.95	1.56	.1126
SD/PD/Relapse	255	1.74	1.25	2.41	.0009
Missing	22	2.24	0.82	6.13	.1175